Twist Bioscience price target lowered to $52 from $55 at Barclays

Barclays lowered the firm’s price target on Twist Bioscience (TWST) to $52 from $55 and keeps an Overweight rating on the shares. The company reported a solid quarter with a fiscal 2025 guide better than expectations despite a tough budgetary macro environment, the analyst tells investors in a research note. The firm sees the business as still on track to deliver 50% gross margins in Q4.